General Clinical Chemistry Analyzers and Accessories
Abcam LGK974, 5MG
MW 396.4 Da, Purity >=98%. LGK-974 is a potent and specific inhibitor of Porcupine (porcn), a Wnt-specific acyltransferase (IC₅₀ = ~0.4 nM). GK974 potently inhibits Wnt signaling, has strong efficacy in rodent tumor models, and is well-tolerated. In addition, head and neck cancer cell lines with loss-of-function mutations in the Notch signaling pathway have a high response rate to LGK974.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Calcein Blue AM acetate, 1MG
MW 465.4 Da, Purity >95%. Blue fluorescent cell viability probe which won't overlap with green fluorescence from other probes. Penetrates live cell membranes and is virtually non-fluorescent. Upon ubiquitous esterase enzyme activity it produces a bright blue fluorescent that is trapped in live cells - convenient for measurement by epifluorescence light microscopy or flow cytometry. Useful to measure the total number of live versus dead cells - dye leaks out quickly due to the compromised membrane in dead cells resulting in no staining.
The product is subject to the following: Abcam Restricted Use Statement
Abcam EHop-016, Rac GTPase inhibitor, 5MG
MW 430.5 Da, Purity >98%. Specific Rac GTPase inhibitor. Analog of NSC-23766 (ab142161). Approximately 100-fold more potent against Rac (IC₅₀ = 1.1 μM) than NSC-23766. Specific for Rac1 and Rac3 at concentrations of ≤5 μM. At higher concentrations (10μM) inhibits the the related Rho GTPase Cdc42. Also inhibits the activity of the Rac downstream effector p21-activated kinase (PAK), lamellipodia extension, and cell migration in metastatic cancer cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam PF-573228, 50MG
MW 491.5 Da, Purity >=98%. Potent and selective FAK inhibitor (IC₅₀ = 4 nM versus recombunant catalytic fragent). Blocks FAK Tyr397phosphorylation in cultured cells (IC₅₀ = 30–100 nM). Shows 50 - 250-fold selectivity for FAK aginst a panel of 40 recombinant kinases. Inhibits chemotactic and haptotactic cell migration.
The product is subject to the following: Abcam Restricted Use Statement
Abcam URMC-099, 25MG
MW 421.5 Da, Purity >98%. Novel orally bioavailable, brain penetrant mixed lineage kinase (MLK) inhibitor (IC₅₀ values of 19, 42, 14, and 150 nM for MLK1, MLK2, MLK3, and the related MLK family member DLK, respectively). Inhibits multiple kinase pathways including LRRK2 (IC₅₀ = 11 nM). Decreases the production of inflammatory cytokines in cultured microglia exposed to HIV-1 Tat. Reduces fMLP-induced chemotaxis of neutrophil from wild-type C57Bl/6 mice. Facilitates Amyloid-β Clearance in a Murine Model of Alzheimer's Disease.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Miglustat hydrochloride, 1MG
MW 255.74 Da, Purity >=98%. An inhibitor of the N-linked oligosaccharide processing enzymes α-glucosidase I and II. It inhibits rat testicular enzymes ceramide-glucosyltransferase and beta-glucosidase 2 with IC₅₀ values of 32 and 81 μM respectively. Miglustat is used for the treatment of type 1 Gaucher's disease. It is an inhibitor of HIV replication in vitro. It shows activity against SARS-CoV-2 in vitro with EC₅₀ values in the micromolar range.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Daclatasvir (BMS-790052), HCV NS5A protein inhibitor, 25MG
MW 738.9 Da, Purity =97%. Daclatasvir a potent, direct acting, small molecule inhbitor of HCV NS5A protein. It inhbibits replicons expressing a wide range of HCV genotypes with EC₅₀ values in the pM range (9 and 71 pM against the 1b and 2a genotypes, respectively). It also inhibits infection by the JFH-1 genotype 2a virus in cultured cells. Daclatasvir is thought to inhibit relication of the HCV viral genome by affecting the subcellular localization of HCV NS5A and preventing its incorporation into relication complexes. In HCV-infected Huh7 cells, Daclatasvir (1 nM) inhibits viral RNA synthesis and viron assembly. Daclatasvir displays moderate activity against the OAT1B1 (IC₅₀ = 1.5 μM) and OAT1B3 (IC₅₀ = 3.27 μM) organic anion transporters.
The product is subject to the following: Abcam Restricted Use Statement
Nova Biomedical Corporation Cartridges for BioProfile FLEX Analyzer
BioProfile FLEX Gas Electrolyte Calibrator Cartridge
Abcam YM-155, survivin inhibitor, 25MG
MW 443.3 Da, Purity >98%. Novel small molecule potent survivin suppressant. Inhibits survivin promoter activity (IC₅₀ = 0.54 nM) and down-regulates survivin in vitro and in vivo. Induces apoptosis in human tumor cell lines in vitro at 10 nM, with little effect on other IAP or Bcl-2 family members.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Daclatasvir (BMS-790052), HCV NS5A protein inhibitor, 5MG
MW 738.9 Da, Purity =97%. Daclatasvir a potent, direct acting, small molecule inhbitor of HCV NS5A protein. It inhbibits replicons expressing a wide range of HCV genotypes with EC₅₀ values in the pM range (9 and 71 pM against the 1b and 2a genotypes, respectively). It also inhibits infection by the JFH-1 genotype 2a virus in cultured cells. Daclatasvir is thought to inhibit relication of the HCV viral genome by affecting the subcellular localization of HCV NS5A and preventing its incorporation into relication complexes. In HCV-infected Huh7 cells, Daclatasvir (1 nM) inhibits viral RNA synthesis and viron assembly. Daclatasvir displays moderate activity against the OAT1B1 (IC₅₀ = 1.5 μM) and OAT1B3 (IC₅₀ = 3.27 μM) organic anion transporters.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ticagrelor, P2Y12 receptor antagonist, 50MG
MW 522.6 Da, Purity >98%. Reversible antagonist of the platelet purinergic P2Y12 receptor, the main receptor responsible for ADP-induced platelet aggregation. Changes the conformation of the P2Y12 receptor, resulting in reversible, concentration dependent inhibition of the receptor.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB-525334, TGFBR1 inhibitor., 25MG
MW 343.4 Da, Purity >98%. Cell permeable, potent, selective transforming growth factor beta 1 receptor (ALK5) (IC₅₀ = 14.3 nM) and ALK4 (IC₅₀ = 58.5 nM) inhibitor, with no activity at ALK2, 3 and 6 (IC₅₀ > 10 μM). Blocks fibrosis and renal injury markers in a puromycin-induced nephritis model. Causes significant attenuation in Smad2/3 nuclear translocation and a decrease in CTGF-expressing cells, myofibroblast proliferation and type 1 collagen deposition resulting in an overall attenuation in bleomycin-induced pulmonary fibrosis.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Apremilast, 25MG
MW 460.5 Da, Purity >98%. Ppotent PDE4 (phosphodiesterase 4) inhibitor (IC₅₀ = 74 nM). It reduces TNF-α production in human synovial cells and significantly suppresses experimental arthritis.
The product is subject to the following: Abcam Restricted Use Statement